Key result
Endomyocardial biopsy was associated with a lower risk of 90-day death or heart transplantation, while lack of heart failure medications independently worsened prognosis.
Why the study?
Routine application of endomyocardial biopsy in acute myocarditis is controversial, and its value in fulminant presentation is unknown.
Does endomyocardial biopsy improve the prognosis (death or heart transplantation) in patients with acute myocarditis with fulminant presentation?
Cohort (n=646)
Yes
Does endomyocardial biopsy improve the prognosis (death or heart transplantation) in patients with acute myocarditis with fulminant presentation?
Answers are grounded in this paper and cite their sources.
Endomyocardial biopsy in fulminant acute myocarditis is associated with improved 90-day survival, likely driven by higher utilization of evidence-based heart failure medications in biopsied patients.
Background Although routine application of endomyocardial biopsy (EB) in acute myocarditis is controversial, its value in fulminant presentation, which is uncommon but lethal, is unknown. Objectives This study aims to elucidate clinical value of EB obtaining histological diagnosis in acute myocarditis with fulminant presentation (AMFP). Methods This nationwide retrospective cohort study included acute myocarditis patients who were hospitalized and required catecholamine infusion or mechanical circulatory support from 235 teaching hospitals across Japan between April 2012 and March 2017. The prognostic predictors for death or heart transplantation within 90 days on the basis of clinical and pathologic findings were determined using the Kaplan-Meier method and Cox regression analysis. Results A total of 646 patients clinically diagnosed as AMFP were studied (median age, 54 years; 40% female), of whom 317 patients had histological diagnosis by EB while the remaining 329 had not underwent EB. Age, CK-MB and LVEF on admission, incidences of brady-arrhythmia and/or tachy-arrhythmia were similar in these two groups. However, AMFP without EB had significantly worse prognosis compared with those with histological diagnosis confirmed by EB (log-rank, p<0.0001) (Figure). Multivariate Cox regression analysis in overall AMFP patients showed that EB and evidence-based heart failure medications contributed to better prognosis whereas the use of corticosteroid or mechanical circulatory support did not. Lack of any heart failure medications was more frequent in AMFP without EB (49.8%) than in those with EB (26.1%), and it was strongly and independently associated with a worse prognosis in AMFP (HR=4.49, 95% CI: 3.26-6.18, p<0.0001). Conclusions The results of this study demonstrated that AMFP patients without EB are at a higher risk for death or heart transplantation than those with EB. Even in this lethal myocarditis, evidence-based heart failure medications, but not mechanical circulatory support, improve its prognosis significantly.
No takes yet. Share an insight, caveat, or question.
Takei et al. (2025) conducted a cohort in Acute myocarditis with fulminant presentation (n=646). Endomyocardial biopsy (EB) vs. No endomyocardial biopsy was evaluated on Death or heart transplantation within 90 days (p=<0.0001). Endomyocardial biopsy was associated with a lower risk of 90-day death or heart transplantation, while lack of heart failure medications independently worsened prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: